Biofrontera

Biofrontera Short-term Debt

The Short-Term Debt of Biofrontera (B8FK.DE) as of Nov 21, 2026 is 671,000.00 EUR. In the previous year, Short-Term Debt was 436,000.00 EUR — a change of 53.90% (higher).

Short-term Debt

671,000.00EUR

YoY

53.90%

Last updated:

Short-Term Debt of Biofrontera is 2025 671,000.00 EUR. Short-Term Debt of Biofrontera was 2024 436,000.00 EUR. It decreases by 53.90% higher compared to the previous year.

The Biofrontera Short-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Short-term Debt
Date
Short-term Debt
Jan 1, 2018
165,000.00 EUR
Jan 1, 2019
1.21 M EUR
Jan 1, 2020
1.14 M EUR
Jan 1, 2021
2.45 M EUR
Jan 1, 2022
446,000.00 EUR
Jan 1, 2023
468,000.00 EUR
Jan 1, 2024
436,000.00 EUR
Jan 1, 2025
671,000.00 EUR
The Biofrontera Short-term Debt history
YEARShort-term DebtYoY
671,000.00EUR+53.90%
436,000.00EUR-6.84%
468,000.00EUR+4.93%
446,000.00EUR-81.79%
2.45 MEUR+115.01%
1.14 MEUR-6.02%
1.21 MEUR+634.55%
165,000.00EUR-2.94%
170,000.00EUR-38.94%
278,424.00EUR-66.94%
842,174.00EUR-31.23%
1.22 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biofrontera Stock analysis

What does Biofrontera do? Biofrontera AG generates revenue by developing, selling, and distributing dermatological drugs and medical cosmetics for skin care, protection, and treatment. The company markets its portfolio which includes Ameluz for the photodynamic therapy of actinic keratoses, the PDT lamp BF-RhodoLED used in conjunction with Ameluz treatment, and Belixos, a herbal dermatological cream for conditions such as insect bites, burns, neurodermatitis, and psoriasis. These products address the needs of patients and healthcare providers seeking treatments for skin diseases and regenerative care of damaged skin. The firm also engages in the clinical development of drug candidates to expand its future revenue streams. This includes BF-derm1, a tablet containing an inhibitor that blocks histamine synthesis to prevent allergic reactions, and BF1, a selective serotonin receptor agent aimed at preventing migraines. Through its five wholly owned subsidiaries, notably B, Biofrontera AG supports these development and distribution activities from its headquarters in Leverkusen, Nordrhein-Westfalen. Biofrontera is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biofrontera stock

Short-Term Debt of Biofrontera is 671,000.00 EUR in 2025.

Short-Term Debt of Biofrontera changed from 436,000.00 EUR to 671,000.00 EUR, representing a 53.90% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Short-Term Debt Biofrontera since 2006 – with annual values, charts, and detailed analysis.

Short-term debt represents borrowings due within one year. High short-term debt relative to cash can signal liquidity risk.

Short-Term Debt's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Short-Term Debt's Biofrontera historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Biofrontera

All Key Metrics — Biofrontera